Bolt Biotherapeutics, Inc. (BOLT): Price and Financial Metrics


Bolt Biotherapeutics, Inc. (BOLT): $1.80

0.05 (+2.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BOLT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BOLT Stock Price Chart Interactive Chart >

Price chart for BOLT

BOLT Price/Volume Stats

Current price $1.80 52-week high $19.29
Prev. close $1.75 52-week low $1.39
Day low $1.68 Volume 120,600
Day high $1.83 Avg. volume 243,279
50-day MA $2.14 Dividend yield N/A
200-day MA $7.04 Market Cap 67.45M

Bolt Biotherapeutics, Inc. (BOLT) Company Bio


Bolt Biotherapeutics, Inc. operates as a biotechnology company. The Company develops immune-stimulating antibody conjugates, a new class of cancer therapeutics, which systemically-administered and uncover the immune system to induce anti-tumor immunity. Bolt Biotherapeutics serves healthcare industry in the United States.


BOLT Latest News Stream


Event/Time News Detail
Loading, please wait...

BOLT Latest Social Stream


Loading social stream, please wait...

View Full BOLT Social Stream

Latest BOLT News From Around the Web

Below are the latest news stories about Bolt Biotherapeutics Inc that investors may wish to consider to help them evaluate BOLT as an investment opportunity.

Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...

Benzinga | February 21, 2022

Companies Like Bolt Biotherapeutics (NASDAQ:BOLT) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | February 12, 2022

Bolt Biotherapeutics to Participate in Upcoming February Conferences

REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present at two upcoming conferences in February: Guggenheim 2022 Oncology Virtual ConferenceFireside chat on Wednesday, Feb. 9, at 10:00 a.m. PT (1:00 p.m. ET)Virtual 1

Yahoo | February 2, 2022

7 Little-Known Penny Stocks That Could Take Off Any Moment

Penny stocks are incredibly risky and should only be considered with speculation funds.

Josh Enomoto on InvestorPlace | January 27, 2022

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb''s PD-1 checkpoint inhibitor OPDIVO® (nivolumab). In parallel, Bolt continues to advance the single-agent portion of the study, following the presentation of interim dose-escalation data at the European Society of Medical Oncology Immuno-Oncology (ESMO I-O) Congres...

Benzinga | January 6, 2022

Read More 'BOLT' Stories Here

BOLT Price Returns

1-mo 10.43%
3-mo -49.86%
6-mo -80.00%
1-year -89.72%
3-year N/A
5-year N/A
YTD -63.27%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4201 seconds.